Abstract
G-protein coupled receptors (GPCRs) are commonly present at the plasma membrane and their signaling modulates excitation-contraction coupling and excitation-secretion coupling of excitable and non-excitable cells of the cardiovascular system. Their effect on excitation-gene expression coupling was attributed, in part, to the nuclear translocation of their signaling and/or to the entry into the nuclear membrane of the internalized GPCRs. However, the recently established paradigm showed that, in addition to plasma membrane G-proteins, GPCRs exist as native nuclear membranes receptors and they modulate nuclear ionic homeostasis and function. These nuclear membrane GPCRs could function independently of plasma membrane GPCRs. Growing evidence also shows that these nuclear membrane GPCRs contribute to protein synthesis and also undergo changes in pathological conditions. The presence of a GPCR at both the plasma and nuclear membranes and/or only at the nuclear membranes represents a new challenge to better understand their contribution to cell physiology and pathology and, consequently, to the development of new therapeutic drugs targeting this category of receptors.
Keywords: Angiotensin II, endothelin-1, GPCR, neuropeptide Y, nuclear receptors, PAF, prostaglandins, VIP receptors.
Current Vascular Pharmacology
Title:Nuclear Membranes GPCRs: Implication in Cardiovascular Health and Diseases
Volume: 12 Issue: 2
Author(s): Ghassan Bkaily, Johny Al-Khoury and Danielle Jacques
Affiliation:
Keywords: Angiotensin II, endothelin-1, GPCR, neuropeptide Y, nuclear receptors, PAF, prostaglandins, VIP receptors.
Abstract: G-protein coupled receptors (GPCRs) are commonly present at the plasma membrane and their signaling modulates excitation-contraction coupling and excitation-secretion coupling of excitable and non-excitable cells of the cardiovascular system. Their effect on excitation-gene expression coupling was attributed, in part, to the nuclear translocation of their signaling and/or to the entry into the nuclear membrane of the internalized GPCRs. However, the recently established paradigm showed that, in addition to plasma membrane G-proteins, GPCRs exist as native nuclear membranes receptors and they modulate nuclear ionic homeostasis and function. These nuclear membrane GPCRs could function independently of plasma membrane GPCRs. Growing evidence also shows that these nuclear membrane GPCRs contribute to protein synthesis and also undergo changes in pathological conditions. The presence of a GPCR at both the plasma and nuclear membranes and/or only at the nuclear membranes represents a new challenge to better understand their contribution to cell physiology and pathology and, consequently, to the development of new therapeutic drugs targeting this category of receptors.
Export Options
About this article
Cite this article as:
Bkaily Ghassan, Al-Khoury Johny and Jacques Danielle, Nuclear Membranes GPCRs: Implication in Cardiovascular Health and Diseases, Current Vascular Pharmacology 2014; 12 (2) . https://dx.doi.org/10.2174/1570161112666140226120837
DOI https://dx.doi.org/10.2174/1570161112666140226120837 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Fenofibrate on the Concentration and Relative Distribution of LDL Subfractions in Patients with Combined Dyslipidemia
Letters in Drug Design & Discovery Mitophagy and Disease: New Avenues for Pharmacological Intervention
Current Pharmaceutical Design Recent Advances in Endocrine Metabolic Immune Disorders Drug Targeting: An Editorial Overview
Endocrine, Metabolic & Immune Disorders - Drug Targets Novel Oral Anticoagulants: Recommendations for Patient Evaluation, Treatment Initiation, Follow-up and Perioperative Management
Cardiovascular & Hematological Disorders-Drug Targets Fibrates and Microvascular Complications in Diabetes - Insight from the FIELD Study
Current Pharmaceutical Design Progression of Retinopathy in Type 1 Diabetic Women During Pregnancy
Current Diabetes Reviews Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design New Insights for Multifactorial Disease Therapy: The Challenge of the Symbiotic Drugs
Current Drug Therapy QSAR & Complex Network Study of the HMGR Inhibitors Structural Diversity
Current Drug Metabolism Lipid-Lowering Therapy in HIV-Infected Patients: Relationship with Antiretroviral Agents and Impact of Substance-Related Disorders
Current Vascular Pharmacology The Atherosclerosis Time-Line and the Role of the Endothelium
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Inhibition of Tumor Angiogenesis by Antibodies, Synthetic Small Molecules and Natural Products
Current Medicinal Chemistry Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology ADP Receptors-Targets for Developing Antithrombotic Agents
Current Pharmaceutical Design Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Inhibition of Disulfide Reductases as a Therapeutic Strategy
Current Enzyme Inhibition In-Vitro and In-Vivo Pharmacological Activities with Phytochemical Evaluation of Methanolic Extract of Microcos paniculata Stem Barks
Current Drug Therapy Current Problems with Non-Specific COX Inhibitors
Current Pharmaceutical Design Natural Compounds and Drug Discovery: Can Cnidarian Venom Play a Role?
Central Nervous System Agents in Medicinal Chemistry